Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / TNGX - Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

TNGX - Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

Tango Therapeutics Inc.

  • H.C. Wainwright has started Tango Therapeutics ( NASDAQ: TNGX ) with a buy rating citing its use of synthetic lethality to develop cancer candidates.
  • The firm has a $10 price target (~43% upside based on Wednesday's close).
  • Analyst Robert Burns said that the targets the company is focused on could potentially treat large patient populations.
  • He cited TNG908, Tango's ( TNGX ) most advanced candidate, currently in phase 1/2 for MTAP-deleted tumors. Initial data is expected in H1 2023.
  • After determining the optimum dose for TNG908, Tango ( TNGX ) says it will evaluate efficacy in multiple tumor types in specific cohorts, including malignant peripheral nerve sheath tumor, non-small cell lung cancer, mesothelioma, cholangiocarcinoma, and glioblastoma.
  • Seeking Alpha's Quant Rating views Tango ( TNGX ) as a buy with high marks for growth and momentum .

For further details see:

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Stock Information
Company Name: Tango Therapeutics Inc.
Stock Symbol: TNGX
Market: NASDAQ
Menu
TNGX TNGX Quote TNGX Short TNGX News TNGX Articles TNGX Message Board
Get TNGX Alerts

News, Short Squeeze, Breakout and More Instantly...